GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Shanghai Shyndec Pharmaceutical Co 600420.SS · CNY

Health Care · Shanghai · 🇨🇳 China

Compare

8.24

-0.60%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Shanghai Shyndec Pharmaceutical Co

Its shares trade on Shanghai under the ticker 600420.SS. It has been listed since 16 June 2004. In the fiscal year to 31 December 2025, it reported revenue of CN¥9.36bn and net income of CN¥944.4m. At that date it held total assets of CN¥19.23bn and shareholders' equity of CN¥15.70bn.

Shanghai Shyndec Pharmaceutical Co., Ltd. principally engages in the research, development, manufacturing, and sale of pharmaceutical products. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2004-06-16. The firm's main products are antibiotics, circulatory system drugs and biological products, including garlic oil soft capsules, lecithin soft capsules and deep-sea fish oil soft capsules. Its bulk pharmaceutical chemicals (BPCs) include macrolide antibiotics, antiviral, anti-tumor, cardiovascular, hormones and weight loss drugs. The firm also offers topical preparations, such as gynecological suppositories and dermatology preparations.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
16 Jun 2004
Employees
11,492
Website
shyndec.com ↗

Leadership

Pay as last reported

  • Mr. Jihui XuChairman of the Board, since 2024
  • Mr. Yong LiuPresident, Director, since 2021
  • Mr. Xiangchen WangChief Financial Officer
  • Mr. Xianlin LiVice President, General Counsel, since 2022CN¥1.5m
  • Mr. Dongsong WeiVice PresidentCN¥1.6m
  • Mr. Zhongxi ZhangSecretary of the Board
  • Mr. Shuyuan WeiDirector
  • Mr. Wengong ChuIndependent Director
  • Yingqi LiIndependent Director
  • Mr. Fanhong WuIndependent DirectorCN¥160,000

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Headquartered in Shanghai with 11,492 employees
  • Offers a diverse range of pharmaceutical products including antibiotics and biological products
  • Has a long history with an IPO in 2004

Weaknesses

  • Relies on a limited product range including antibiotics and circulatory system drugs
  • Dependent on bulk pharmaceutical chemicals for revenue
  • No mention of digital or online services for financial data

Opportunities

  • Expansion into new markets for pharmaceutical products
  • Growth potential in the health care sector
  • Potential for increased sales of biological products

Threats

  • Competition in the pharmaceutical industry
  • Regulatory changes affecting pharmaceutical manufacturing
  • Dependence on specific product categories may lead to market volatility

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.